Back to Agenda
Drug Repurposing: Where Will it Take Us?
Session Chair(s)
Bruce E Bloom, DDS, JD
President and Chief Science Officer, Cures Within Reach, United States
Drug repurposing includes approved drug indication expansion, drug-like compound repositioning, and drug reformulation strategies to help get medicines to patients faster. Because repositioning leverages sunk costs for compounds that have failed to reach market, and approved drugs can be reformulated or repurposed to treat a different disorder, the cost often times to get the new therapy to market is reduced. Will “repurposing" disrupt the current market? How can academia, industry, and health authorities collaborate to advance drug repurposing efforts? What is needed to overcome economic, patent, and regulatory hurdles to get repurposed drugs to patients faster? These questions and others will be addressed during this DIAmond session by an esteemed panel of representatives from NIH NCATS, Cures Within Reach, industry, and academia.
Learning Objective : Define the concept of drug repurposing; Discuss opportunities and challenges for academia, industry, and health authorities to collaborate to advance drug repurposing efforts; Review the economic, patent, and regulatory hurdles that exist to get repurposed drugs to patients faster.
Speaker(s)
Christine Colvis, PHD
Director, Drug Development Partnership Programs, National Center for Advancing Translational Sciences (NCATS), United States
Funder Perspective
Jill Pulley, MBA
Executive Director, Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, United States
Using Human Genetic Variation to Repurpose Existing Medications for New Diseases
Pamela Hill, MS, PMP
Open Innovation Program Director, Principal Scientist, Emerging Innovations Unit, AstraZeneca, United States
Industry Perspective
K. Gary Barnette, PHD
Senior Vice President of Scientific and Regulatory Affairs, Camargo Pharmaceutical Services, LLC, United States
Industry Perspective
Have an account?